{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T04:21:14Z","timestamp":1794975674370,"version":"4.9.1"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Special Account for Research"},{"DOI":"10.13039\/501100005187","name":"National and Kapodistrian University of Athens","doi-asserted-by":"publisher","award":["DV #12085"],"award-info":[{"award-number":["DV #12085"]}],"id":[{"id":"10.13039\/501100005187","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005187","name":"National and Kapodistrian University of Athens","doi-asserted-by":"publisher","award":["12086"],"award-info":[{"award-number":["12086"]}],"id":[{"id":"10.13039\/501100005187","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>There are limited real-life data regarding the efficacy and safety of rituximab (RTX) as a remission maintenance agent in microscopic polyangiitis (MPA) and granulomatosis-with-polyangiitis (GPA). We aimed to estimate the incidence and risk factors for relapses, as well for serious adverse events (SAEs) in MPA\/GPA patients during RTX maintenance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective cohort of newly diagnosed\/relapsing GPA\/MPA patients who received RTX maintenance (\u22651 RTX cycle, \u22656\u2009months follow-up) following complete remission (BVAS version-3\u2009=\u20090 plus prednisolone \u22647.5\u2009mg\/day) with induction regimens. SAEs included serious infections, COronaVIrus-Disease 2019 (COVID-19)\u2013associated hospitalizations, deaths, cardiovascular events, malignancies and hypogammaglobulinemia. The incidence rates (IRs) and relapse-free survival were estimated through Kaplan\u2013Meier plots. Cox regression was conducted to investigate factors associated with the time-to-relapse.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 101 patients were included: 48% females, 69% GPA, 53% newly diagnosed, median age 63\u2009years. During follow-up (294.5 patient-years, median: 3 RTX cycles), 30 relapses (57% major) occurred among 24 patients (24%, IR 10.2\/100 patient-years). Kidney involvement (adjusted hazard ratio\/aHR: 0.20; 95% CI: 0.06\u20130.74, P\u2009=\u20090.016), prior induction with RTX plus CYC (vs RTX monotherapy: aHR\u2009=\u20090.02; 95% CI: 0.001\u20130.43, P\u2009=\u20090.012) and shorter time interval until complete remission (aHR\u2009=\u20091.07; 95% CI: 1.01\u20131.14, P\u2009=\u20090.023) were associated with decreased relapse risk. We recorded 17 serious infections (IR 5.8\/100 patient-years), 11 COVID-19\u2013associated hospitalizations (IR 3.7\/100 patient-years), 4 malignancies (IR 1.4\/100 patient-years), 6 cardiovascular events (IR 2\/100 patient-years) and 10 deaths (IR 3.4\/100 patient-years).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In this real-world study, relapses during RTX maintenance occurred in approximately 1 out of 4 patients. Kidney involvement, induction with RTX plus CYC, and earlier achievement of complete remission were associated with lower relapse risk. The serious infections rate was consistent with previous reports, whereas an increased rate of COVID-19\u2013associated hospitalizations was observed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae409","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T04:55:06Z","timestamp":1723006506000},"page":"1989-1998","source":"Crossref","is-referenced-by-count":17,"title":["Relapses and serious adverse events during rituximab maintenance therapy in ANCA-associated vasculitis: a multicentre retrospective study"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1310-7902","authenticated-orcid":false,"given":"Chrysoula G","family":"Gialouri","sequence":"first","affiliation":[{"name":"Joint Rheumatology Program, Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, General Hospital of Athens \u201cHippokration\u201d , Athens,","place":["Greece"]},{"name":"Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens , Athens,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5963-3246","authenticated-orcid":false,"given":"Aglaia","family":"Chalkia","sequence":"additional","affiliation":[{"name":"Nephrology Department, General Hospital of Athens \u201cHippokration\u201d , Athens,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6621-6918","authenticated-orcid":false,"given":"Christos","family":"Koutsianas","sequence":"additional","affiliation":[{"name":"Joint Rheumatology Program, Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, General Hospital of Athens \u201cHippokration\u201d , Athens,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1274-0909","authenticated-orcid":false,"given":"Katerina","family":"Chavatza","sequence":"additional","affiliation":[{"name":"Joint Rheumatology Program, Clinical Immunology-Rheumatology Unit, 4th Department of Medicine, National and Kapodistrian University of Athens School of Medicine, Attikon General Hospital , Athens,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Argyriou","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Sismanoglio General Hospital , Athens,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3612-9394","authenticated-orcid":false,"given":"Alexandros","family":"Panagiotopoulos","sequence":"additional","affiliation":[{"name":"Joint Rheumatology Program, Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, General Hospital of Athens \u201cHippokration\u201d , Athens,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3006-9362","authenticated-orcid":false,"given":"Anastasios","family":"Karamanakos","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, \u201cEvangelismos\u201d General Hospital , Athens,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0884-1870","authenticated-orcid":false,"given":"Aikaterini","family":"Dimouli","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, \u201cEvangelismos\u201d General Hospital , Athens,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2532-0047","authenticated-orcid":false,"given":"Christina","family":"Tsalapaki","sequence":"additional","affiliation":[{"name":"Joint Rheumatology Program, Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, General Hospital of Athens \u201cHippokration\u201d , Athens,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7489-7776","authenticated-orcid":false,"given":"Konstantinos","family":"Thomas","sequence":"additional","affiliation":[{"name":"Joint Rheumatology Program, Clinical Immunology-Rheumatology Unit, 4th Department of Medicine, National and Kapodistrian University of Athens School of Medicine, Attikon General Hospital , Athens,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippos","family":"Orfanos","sequence":"additional","affiliation":[{"name":"Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens , Athens,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pagona","family":"Lagiou","sequence":"additional","affiliation":[{"name":"Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens , Athens,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Katsikas","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, \u201cEvangelismos\u201d General Hospital , Athens,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyriaki","family":"Boki","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Sismanoglio General Hospital , Athens,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9812-4671","authenticated-orcid":false,"given":"Dimitrios","family":"Boumpas","sequence":"additional","affiliation":[{"name":"Joint Rheumatology Program, Clinical Immunology-Rheumatology Unit, 4th Department of Medicine, National and Kapodistrian University of Athens School of Medicine, Attikon General Hospital , Athens,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Petras","sequence":"additional","affiliation":[{"name":"Nephrology Department, General Hospital of Athens \u201cHippokration\u201d , Athens,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2288-3863","authenticated-orcid":false,"given":"Dimitrios","family":"Vassilopoulos","sequence":"additional","affiliation":[{"name":"Joint Rheumatology Program, Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, General Hospital of Athens \u201cHippokration\u201d , Athens,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"key":"2025040212091927300_keae409-B1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41584-022-00819-y","article-title":"Genetics of ANCA-associated vasculitis: role in pathogenesis, classification and management","volume":"18","author":"Trivioli","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2025040212091927300_keae409-B2","doi-asserted-by":"crossref","first-page":"707.1","DOI":"10.1136\/annrheumdis-2022-eular.3481","article-title":"POS0832 mortality trends in ANCA-Associated Vasculitides (AAVs): data from a contemporary, multicenter ANCA registry","volume":"81","author":"Koutsianas","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025040212091927300_keae409-B3","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1136\/annrheumdis-2016-210942","article-title":"Mortality in ANCA-associated vasculitis: ameta-analysis of observational studies","volume":"76","author":"Tan","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025040212091927300_keae409-B4","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.3390\/jcm10173773","article-title":"Rituximab induction and maintenance in ANCA-associated vasculitis: state of the art and future perspectives","volume":"10","author":"Treppo","year":"2021","journal-title":"J Clin Med"},{"key":"2025040212091927300_keae409-B5","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/ard-2023-224623","article-title":"Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials","volume":"83","author":"Delestre","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025040212091927300_keae409-B6","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener granulomatosis: an analysis of 158 patients","volume":"116","author":"Hoffman","year":"1992","journal-title":"Ann Intern Med"},{"key":"2025040212091927300_keae409-B7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/annrheumdis-2013-203927","article-title":"Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials","volume":"74","author":"Robson","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025040212091927300_keae409-B8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ekir.2019.10.005","article-title":"Relapse in Anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis","volume":"5","author":"Salama","year":"2020","journal-title":"Kidney Int Rep"},{"key":"2025040212091927300_keae409-B9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"2025040212091927300_keae409-B10","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/annrheumdis-2014-206404","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial","volume":"74","author":"Jones","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025040212091927300_keae409-B11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025040212091927300_keae409-B12","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/rheumatology\/keu452","article-title":"Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis","volume":"54","author":"Alberici","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2025040212091927300_keae409-B13","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/rheumatology\/keaa541","article-title":"Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models","volume":"60","author":"McClure","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2025040212091927300_keae409-B14","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/rheumatology\/ket381","article-title":"Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients","volume":"53","author":"Charles","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"2025040212091927300_keae409-B15","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1002\/art.34583","article-title":"Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Smith","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2025040212091927300_keae409-B16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025040212091927300_keae409-B17","doi-asserted-by":"crossref","first-page":"84","DOI":"10.31138\/mjr.31.1.84","article-title":"Development of an ANCA-associated vasculitides patient registry in Greece","volume":"31","author":"Thomas","year":"2020","journal-title":"Mediterr J Rheumatol"},{"key":"2025040212091927300_keae409-B18","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham Vasculitis Activity Score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2025040212091927300_keae409-B19","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1093\/rheumatology\/keac175","article-title":"Psychometric properties of outcome measurement instruments for ANCA-associated vasculitis: a systematic literature review","volume":"61","author":"Berti","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025040212091927300_keae409-B20","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/acr.22456","article-title":"Validation of the rheumatic disease comorbidity index","volume":"67","author":"England","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025040212091927300_keae409-B21","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"2025040212091927300_keae409-B22","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2010050477","article-title":"Histopathologic classification of ANCA-associated glomerulonephritis","volume":"21","author":"Berden","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2025040212091927300_keae409-B23","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"2025040212091927300_keae409-B24","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025040212091927300_keae409-B25","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard-2022-223559","article-title":"Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial","volume":"82","author":"Smith","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025040212091927300_keae409-B26","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1136\/annrheumdis-2019-216863","article-title":"Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis","volume":"79","author":"Smith","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025040212091927300_keae409-B27","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2215\/CJN.06250519","article-title":"Treatment of Relapses in ANCA-associated vasculitis","volume":"14","author":"McClure","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025040212091927300_keae409-B28","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/art.39104","article-title":"Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids","volume":"67","author":"Miloslavsky","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025040212091927300_keae409-B29","first-page":"201","article-title":"Renal involvement at baseline can predict major renal relapse in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"38(Suppl 124)","author":"Felicetti","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2025040212091927300_keae409-B30","doi-asserted-by":"crossref","first-page":"102467","DOI":"10.1016\/j.jaut.2020.102467","article-title":"Microscopic polyangiitis: clinical characteristics and long-term outcomes of 378 patients from the French Vasculitis Study Group Registry","volume":"112","author":"Nguyen","year":"2020","journal-title":"J Autoimmun"},{"key":"2025040212091927300_keae409-B31","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ekir.2019.01.004","article-title":"Understanding long-term remission off therapy in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"4","author":"Hogan","year":"2019","journal-title":"Kidney Int Rep"},{"key":"2025040212091927300_keae409-B32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"2025040212091927300_keae409-B33","doi-asserted-by":"crossref","first-page":"100178","DOI":"10.1016\/j.jtauto.2022.100178","article-title":"Adding low dose cyclophosphamide to rituximab for remission-induction may prolong relapse-free survival in patients with ANCA vasculitis: a retrospective study","volume":"6","author":"Ysermans","year":"2023","journal-title":"J Transl Autoimmun"},{"key":"2025040212091927300_keae409-B34","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ekir.2017.11.004","article-title":"Combination therapy with rituximab and cyclophosphamide for remission induction in ANCA vasculitis","volume":"3","author":"Cortazar","year":"2018","journal-title":"Kidney Int Rep"},{"key":"2025040212091927300_keae409-B35","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/art.40776","article-title":"Effect of disease activity at three and six months after diagnosis on long-term outcomes in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"71","author":"Gopaluni","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025040212091927300_keae409-B36","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/annrheumdis-2015-208073","article-title":"Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type","volume":"75","author":"Unizony","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025040212091927300_keae409-B37","doi-asserted-by":"crossref","first-page":"1110548","DOI":"10.3389\/fmed.2023.1110548","article-title":"Incidence of serious infections in patients with ANCA-associated vasculitis receiving immunosuppressive therapy: a systematic review and meta-analysis","volume":"10","author":"Vassilopoulos","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2025040212091927300_keae409-B38","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13075-021-02452-8","article-title":"Serious infections in ANCA-associated vasculitides in the biologic era: real-life data from a multicenter cohort of 162 patients","volume":"23","author":"Thomas","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2025040212091927300_keae409-B39","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/ard-2022-223401","article-title":"Risk factors for serious infections in ANCA-associated vasculitis","volume":"82","author":"Odler","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025040212091927300_keae409-B40","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard-2023-224489","article-title":"Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: a randomised trial","volume":"83","author":"Zonozi","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025040212091927300_keae409-B41","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","article-title":"Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"80","author":"Strangfeld","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2025040212091927300_keae409-B42","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s00296-022-05177-2","article-title":"Managing ANCA-associated vasculitis during COVID-19 pandemic: a single-center cross-sectional study","volume":"42","author":"Samanta","year":"2022","journal-title":"Rheumatol Int"},{"key":"2025040212091927300_keae409-B43","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1007\/s10067-023-06769-4","article-title":"Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases","volume":"42","author":"Papagoras","year":"2023","journal-title":"Clin Rheumatol"},{"key":"2025040212091927300_keae409-B44","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/ckj\/sfab229","article-title":"Association of anti-neutrophil cytoplasmic antibody-associated vasculitis and cardiovascular events: a population-based cohort study","volume":"15","author":"Massicotte-Azarniouch","year":"2022","journal-title":"Clin Kidney J"},{"key":"2025040212091927300_keae409-B45","doi-asserted-by":"crossref","first-page":"e001267","DOI":"10.1161\/JAHA.114.001267","article-title":"Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis","volume":"3","author":"Hsue","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"2025040212091927300_keae409-B46","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11926-023-01123-8","article-title":"Cardiovascular disease in anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"26","author":"Sayer","year":"2024","journal-title":"Curr Rheumatol Rep"},{"key":"2025040212091927300_keae409-B47","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/annrheumdis-2016-209925","article-title":"Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis","volume":"76","author":"van Daalen","year":"2017","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae409\/58927687\/keae409.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/4\/1989\/58927687\/keae409.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/4\/1989\/58927687\/keae409.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T16:24:01Z","timestamp":1743611041000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/4\/1989\/7728498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,8,6]]},"published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae409","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,8,6]]}}}